CN101462999A - Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof - Google Patents
Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof Download PDFInfo
- Publication number
- CN101462999A CN101462999A CNA2007100946047A CN200710094604A CN101462999A CN 101462999 A CN101462999 A CN 101462999A CN A2007100946047 A CNA2007100946047 A CN A2007100946047A CN 200710094604 A CN200710094604 A CN 200710094604A CN 101462999 A CN101462999 A CN 101462999A
- Authority
- CN
- China
- Prior art keywords
- fluoro
- heptane
- azabicyclo
- carboxylic acid
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a fluoro or difluoro-2-diazabicyclo (2.2.1) heptane-3-carboxylic acid derivative and a preparing method thereof. A chemical structural formula is shown in the right formula. 5-hydroxyl group-2-diazabicyclo (2.2.1) heptane-3-carboxylic ester or 5-carbonyl-2-diazabicyclo (2.2.1) heptane-3-carboxylic ester is adopted for obtaining 5-fluorine-2-diazabicyclo (2.2.1) heptane-3-carboxylic ester or 5, 5-difluoro-2-diazabicyclo (2.2.1) heptane-3-carboxylic ester after the fluorination. And then carboxylic acid is obtained after hydrolysis. When the protection is drawn off, free amino compounds are obtained. By the transformation of changing protecting groups or ester groups, a target product is obtained. The derivative of the invention is mainly used as an intermediate or a structural fragment during the drug synthesis.
Description
Technical field:
The present invention relates to fluoro or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and preparation method, 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and 5 particularly, 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and preparation method thereof.
Background technology:
The bridged ring class formation couples together the pharmacophore unit of key or is incorporated in its rigid structure, formation has the molecule of special space configuration conformation, the space structure that can mate different biomacromolecules in the organism, produce different biological activity or effectiveness, a lot of compounds have different biological activitys, so have wide application value, particularly in the drug research process as template compound.The endocyclic compound that contains 2-azabicyclo structure is had various biological activitys by a lot of experimental results show that, with the lower section be in partial monopoly and the document disclosed and with the more closely-related examples of the technology of the present invention.
Patent WO2005042533 reported contain azabicyclo 2-cyano group Pyrrolidine amides formula 1 as the inhibition activity of dipeptide peptidase-IV (DPP_IV) with as the pharmaceutical cpd, the particularly diabetes (NIDDM) of relying on of dipeptide peptidase-IV (DPP_IV) relative disease as non-insulin.
Patent US5260293j has reported pyrazine, pyridazine, the muscarinic acetylcholine acceptor that the azabicyclic derivatives formula 2 of pyrimidine can the excitomotor center nerve, thereby can be used for treating nervus centralis or psychotic disorder, as, degenerative brain disorder, motion function is excited, and is demented etc.
Patent US5583140 report dicyclic compound formula 3 has the exciting characteristic of nicotine receptor or increases the biological activitys such as secretion of nerve conduction thing; thereby can be used for the nervus centralis disorder disease; perhaps can increase patient's nicotine receptor, the neuroprotective cell.
WO2006096807 has reported that the Azabicyclic compounds formula 4 as figure is antagonists of integrin alpha 4 acceptors, the antagonist of α 4 β 1 and α 4 β 7 acceptors particularly, these compounds can be used for treating the relevant disease of antagonist of integrin alpha 4 acceptors, as inflammation, autoimmune disorder, or the hyperplasia venereal disease becomes.
EP0978280 has reported that the Azabicyclic compounds formula 5 as figure is Nicotine acetyl choline receptor agonists, thereby can be used for treating nerve degenerative diseases as, degenerative brain disorder, parkinsonism, and analgesia etc.
Document J.Med.Chem.; EN; 34; 1; 1991; The analogue of 140-151 report compound formula 6 is 5-HT3 receptor antagonists, be the 5-HT3 receptor antagonist and a large amount of medicines that applies to the cancer chemotherapy vomiting is arranged clinically, and this class antagonist also has the potential migraine that applies to, schizophrenia and anxiety disorder.
Document J.Med.Chem.; EN; 40; 12; 1997; 1906-1918., report that this a series of Azabicyclic compounds formula 7 can suppress human leukocyte elastase, and lipid peroxidation, thereby stop because pulmonary emphysema are had difficulty in breathing the pulmonary lesion that tissue fibrosis causes.
Bioorg.Med.Chem.Lett.; EN; 7; 15; 1997; 1989-1994. report compound formula 8 arrhythmia activity are that potassium and calcium channel stop characteristic simultaneously.Bioorganic ﹠amp; Medicinal Chemistry Letters 11 (2001) 2597-2602. have reported that structural formula 9 is gonadotropin releasing hormone (GnRH; Or LHRH) non-peptide receptoroid antagonist is expected to be used for the treatment of the cancer that hormone relies on, endometriosis, fibroma uteri etc.
Bioorg.Med.Chem.Lett.; EN; 14; 3; 2004; 591-596. azabicyclo amino acid sulphur county amide compound formula 11 is antagonists of integrin alpha 4 acceptors, the antagonist of α 4 β 1 and α 4 β 7 acceptors particularly, these compounds can be used for treating the relevant disease of antagonist of integrin alpha 4 acceptors, as inflammation, autoimmune disorder, or the hyperplasia venereal disease becomes.
Bioorg.Med.Chem.Lett.; EN; 15; 15; 2005; 3501-3505. report formula 11 is melanocortin-4receptor (MC4R) selective agonists, is expected to be used for the treatment of obesity or sexual dysfunction.
The antagonist that the compound formula 12 of patent EP937069 report and analogue thereof are neurokinin, thereby be the medicine of potential treatment respiratory tract disease, as asthma.Bioorg.Med.Chem.; EN; 13; 24; 2005; 6693-6702. the compound formula 13 of report, Bioorg.Med.Chem.; EN; 14; 12; 2006; 4208-4216. the compound formula 14 of report is the antagonist of integrin alpha 4 acceptors, particularly the antagonist of α 4 β 1 and α 4 β 7 acceptors, these compounds can be used for treating the relevant disease of antagonist of integrin alpha 4 acceptors, as inflammation, autoimmune disorder, or the hyperplasia venereal disease becomes.
Though we can see that the azabicyclo structure finds in a large amount of active compounds from top example, yet, all have only hydrophobic groups such as carbon atom and hydrogen atom in the structure of present dicyclic compound, because the rigidity of structure, therefore these compounds have certain limitation as the drug research template time, need specific structural modification further to improve its quasi-medicated property matter.Given this, we introduce fluorine element and have prepared the azabicyclo structural compounds of new class in template.Because the introduction of fluorine atom, not only changed the physicals of compound, the more important thing is the internal metabolism that has changed this series compound, distribute and stability, simultaneously, because fluorine atom can also form hydrogen bond with the intravital amino acid of biology, thereby may change effect performance or the mechanism of biomacromolecule in compound and the body.
Summary of the invention:
The purpose of this invention is to provide a kind of fluoro or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and preparation method thereof, mainly be 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative or 5,5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and preparation method thereof.Mainly solving 2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative has only hydrophobic groups such as carbon atom and hydrogen atom, causes the technical problem of metabolic stability difference.
Fluoro or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, chemical structural formula is as follows:
R
1For replacing functional group or amino protecting group, as hydrogen (H), 2,4-dimethoxy-benzyl, benzyl, tertbutyloxycarbonyl (Boc), carbobenzoxy-(Cbz) (Cbz).
R2 is for replacing functional group, as hydrogen (H), methyl, and ethyl, benzyl, 2, a kind of in the 4-dimethoxy-benzyl;
X is fluorine atom (F) or hydrogen (H).
The present invention relates to the 5-amino shown in the above-claimed cpd formula I-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative and 5,5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative include but not limited to:
(A-1) (1R, 3S, 4S)-5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester;
(A-2) (1R, 3S, 4S)-5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid; ,
(A-3) (1R, 3S, 4S, 5S)-5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester;
(A-4) (1R, 3S, 4S)-5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-carboxylate methyl ester;
(A-5) (1R, 3S, 4S)-5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-benzyl carboxylate;
(A-6) (1R, 3S, 4S)-5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-carboxylic acid;
(A-7) (1R, 3S, 4S)-5-fluoro-2-(2, the 4-dimethoxy-benzyl)-2-azabicyclo [2.2.1] heptane-3-benzyl carboxylate;
(A-8) (1R, 3S, 4S)-5-fluoro-2-benzyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester;
(B-1) (1R, 3S, 4S)-5,5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester;
(B-2) (1R, 3S, 4S)-5,5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid;
(B-3) (1R, 3S, 4S)-5,5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl esters,
(B-4) (1R, 3S, 4S)-5-fluoro-2-benzyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid;
(B-5) (1R, 3S, 4S)-5,5-two fluoro-2-benzyls-2-azabicyclo [2.2.1] heptane-3-carboxylate methyl ester;
(B-6) (1R, 3S, 4S)-5,5-two fluoro-2-benzyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid;
(B-7) (1R, 3S, 4S)-5,5-two fluoro-2-benzyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester;
(B-8) (1R, 3S, 4S)-5,5-two fluoro-2-carbobenzoxy-(Cbz)s-2-azabicyclo [2.2.1] heptane-3-benzyl carboxylate;
The above-mentioned structural formula of compound of mentioning is as follows:
Above-claimed cpd is the endocyclic compound of a class formation novelty, does not all have its structure of any bibliographical information and synthetic method at present.
5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, 5, the preparation method of 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid and derivative, step is as shown below:
In above-mentioned technology; 5-hydroxyl-2-azabicyclo [2.2.1] heptane-3-carboxylicesters or 5-carbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylicesters are obtained 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylicesters or 5 through fluoridation; 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylicesterss; obtain carboxylic acid through hydrolysis again; if slough protecting group, just can obtain the free aminocompound.Some known chemical processes of process just can realize changing the conversion of protecting group or ester group, obtain target product.
PG protecting group in the formula, as 2, four kinds of 4-dimethoxy-benzyls, benzyl, tertbutyloxycarbonyl (Boc), carbobenzoxy-(Cbz) (Cbz), preferred tertiary butoxy carbonyl (Boc); Rn is a methyl, ethyl, benzyl.
Fluoridation wherein, the solvent of its reaction usefulness is an aprotic solvent, comprises ether, propyl ether, butyl ether, dioxane, 1,2 dimethoxy ether, methylene dichloride, 1,2 ethylene dichloride, chloroform, tetrahydrofuran (THF), benzene, one or more in the toluene, preferred methylene dichloride, ether; Temperature of reaction is from-78 ℃ to 120 ℃; Reaction reagent is diethylin sulfur trifluoride (DAST), two (methoxy ethyl) amido sulfur trifluoride (Deoxofluor (CH3OCH2CH2) 2N-SF3), 4-morpholine sulfur trifluoride (4-morpholinosulfur trifluoride), two (4-morpholinyl) bifluoride sulphur (difluoro-di-morpholin-4-yl-4-sulfane), triphenyl phosphorus/Potassium monofluoride (PPh
3/ a kind of in KF), or two kinds used with.Preferred methylene dichloride is a solvent, and diethylin sulfur trifluoride (DAST) is a fluorination reagent, stirred overnight at room temperature.
The used method that removes protecting group is an ordinary method; remove 2 as the method with catalytic hydrogenation, three kinds of 4-dimethoxy-benzyls, benzyl, uncle's carbobenzoxy-(Cbz) (Cbz) are with acid (hydrochloric acid; trifluoracetic acid etc.) remove 2,4-dimethoxy-benzyl, two kinds of protecting groups of tertbutyloxycarbonyl (Boc).
And for hydrolysis reaction, its solvent is a methyl alcohol, ethanol, propyl alcohol, Virahol, butanols, isopropylcarbinol, the trimethyl carbinol, various alcohols such as methyl cellosolve, acetone, butanone, ether, dioxane, tetrahydrofuran (THF), N, dinethylformamide, methyl-sulphoxide, one or both mixtures in the various polar solvents such as water, the used alkali of hydrolysis is NaOH, KOH, LiOH, Na
2CO
3, K
2CO
3, Li
2CO
3In a kind of.The temperature of hydrolysis reaction is from room temperature to 100 ℃, preferred room temperature to 60 ℃.
Beneficial effect of the present invention: 5-position fluoro or the two fluoric compound for preparing 2-azabicyclo [2.2.1] heptane-3-carboxylic acid first of the present invention, because the introduction of fluorine atom, not only changed the physicals of compound, the more important thing is the internal metabolism that has changed this series compound, distribute and stability, simultaneously, because fluorine atom can also form hydrogen bond with the amino-acid residue of the intravital biomacromolecule of biology, thereby may change effect performance or the mechanism of biomacromolecule in compound and the body.
Embodiment: enumerate embodiment so that the present invention is done detailed description, but the present invention is not limited to these embodiment.
Embodiment 1
(1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps :-78 ℃, with (1R, 3S, 4S, 5R)-5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (1.42g, 5mmol) be dissolved in the dichloromethane solution that the 10mL methylene dichloride is added drop-wise to 1mL diethylin sulfur trifluoride (DAST), stirred 6 hours, be raised to ambient temperature overnight at-78 ℃.After reaction finishes, saturated sodium bicarbonate solution is added in the reaction solution, organic phase is washed with saturated common salt, and anhydrous sodium sulfate drying concentrates, cross post, get product (1R, 3S, 4S, 5S)-and 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.7g, productive rate is 48.9%.
HNMRCDCl
3)δ：5.29-5.08(m，1H)；4.32(d，1H，J＝7.2Hz)；4.18(m，2H)；2.97(s，1H)；2.08-1.97(m，2H)；1.85-1.53(m，2H)；1.42(m，9H)；1.25(m，3H).
MASS：288.2(M+1)
Embodiment 2
((1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: at-78 ℃, with (1R, 3S, 4S, 5R)-5-hydroxyl-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (1.6g, 5mmol) be dissolved in the dichloromethane solution that the 10mL methylene dichloride is added drop-wise to 1g two (methoxy ethyl) amido sulfur trifluoride (Deoxofluor), stirred 6 hours, be raised to ambient temperature overnight at-78 ℃.Reaction is added to saturated sodium bicarbonate solution in the reaction solution after finishing, and organic phase is washed with saturated common salt, anhydrous sodium sulfate drying, concentrate, cross post, get product (1R, 3S, 4S, 5S)-5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.88g, productive rate is 55.3%.
MASS：322.2(M+1)
Embodiment 3
((1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-carbobenzoxy-(Cbz)-2-azabicyclo [2.2.1] heptane-3-benzyl carboxylate
Reaction formula:
Specifically with reference to embodiment 1, reaction solvent ether, fluorination reagent are with diethylin sulfur trifluoride (DAST), and productive rate is 45.3%.
MASS：384.2(M+1)
Embodiment 4
((1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-benzyl-2-azabicyclo [2.2.1] heptane-3-carboxylate methyl ester
Reaction formula:
Specifically with reference to embodiment 1, reaction solvent methylene dichloride, fluorination reagent are with 4-morpholine sulfur trifluoride (4-morpholinosulfur trifluoride), and productive rate is 39.3%.
MASS：264.2(M+1)
Embodiment 5
(1R, 3S, 4S)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Specifically with reference to embodiment 2, the reaction solvent methylene dichloride, fluorination reagent is 51.3% with two (methoxy ethyl) amido sulfur trifluoride (Deoxofluor), productive rate.
MASS：288.2(M+1)
Embodiment 6
(1R, 3S, 4S)-5, the preparation the first step of 5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester reaction: (1R, 3S, 4S)-preparation of 5-carbonyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: at-78 ℃; nitrogen protection; the dichloromethane solution (0.9mL/5mL) of dimethyl sulfoxide (DMSO) was joined in 20 minutes in the dichloromethane solution (0.52/10) of oxalyl chloride; mixed solution stirred after 20 minutes, added (1R, 3S again; 4S; 5R)-and the dichloromethane solution (1.4g is dissolved in the 5mL methylene dichloride) of 5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester, after reaction solution stirs half an hour, the 3.5mL triethylamine is dripped wherein.Reaction solution is raised to room temperature, continues reaction 2 hours, reaction finishes, after the water cancellation, organic phase washing 3 times, dry concentrating crossed post and obtained (1R, 3S, 4S)-5-carbonyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.72g, productive rate is 51%.
HNMR(CDCl3)δ：4.22(m，2H)；4.12(m，1H)；3.01(s，1H)；2.43(m，1H)；2.35(m，1H)；2.21(m，1H)；1.82(d，1H，J＝10.8Hz)；1.45(m，9H)；1.28(m，3H)。
MASS：284.1
The reaction of second step: (1R, 3S, 4S)-5, the preparation of 5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: at-78 ℃, with compound (1R, 3S, 4S, 5R)-5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (1.42g, 5mmol) be dissolved in the dichloromethane solution that the 10mL methylene dichloride is added drop-wise to 1mLDAST, stirred 6 hours, be raised to ambient temperature overnight at-78 ℃.In reaction solution, add the 1mL dehydrated alcohol again, continue to stir 16 hours.After reaction finishes, saturated sodium bicarbonate solution is added in the reaction solution, organic phase is washed with saturated common salt, and anhydrous sodium sulfate drying concentrates, cross post, product (1R, 3S, 4S)-5,5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.8g, productive rate is 53.3%.
HNMR(CDCl3)δ：4.45(m，1H)；4.24-4.19(m，2H)；2.95(m，1H)；2.20-2.11(m，4H)；1.77(m，1H)；1.37-1.60(m，9H)；1.28(m.3H).
MASS：306.1
Embodiment 7
(1R, 3S, 4S)-5, the preparation of 5-two fluoro-2-benzyl carbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylate methyl ester
Reaction formula:
Specifically with reference to embodiment 2, the reaction solvent methylene dichloride, fluorination reagent is 57.8% with two (methoxy ethyl) amido sulfur trifluoride (Deoxofluor), productive rate.
MASS：326.1
Embodiment 8
(1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid
Reaction formula:
Operation steps: with compound (1R, 3S, 4S, 5S)-and 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (0.28,1mmol) be dissolved in 10mL methyl alcohol and the 2mL water, add sodium hydroxide (0.08g again, 2mmol), reaction solution at room temperature stirs and spends the night.After reaction is finished, revolve to steam and remove methyl alcohol, use ethyl acetate extraction, water is transferred pH to 7 with the hydrochloric acid soln of 1mol/L, and lyophilize gets product 0.24g, and productive rate is 96%.
HNMR(CDCl
3)δ：5.37-5.18(d，1H，J＝6Hz)；4.73-4.46(m，1H)；4.12(s，1H)；3.37(s，1H)；2.14-1.91(m，2H)；1.83-1.63(m，1H)1.51(m，9H).
MASS：258.1(M-1)
Embodiment 9
(1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: with compound (1R, 3S, 4S, 5S)-5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (0.29,1mmol) be dissolved in the 20mL salt acid ether, stirred 2 hours.Add saturated sodium bicarbonate aqueous solution, use ethyl acetate extraction, reaction solution be spin-dried for (1R, 3S, 4S, 5S)-5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.16g, productive rate is 85.6%.
HNMR(CDCl3)δ：11.2(s，1H)；9.04(s，1H)；5.33-5.12(dd，1H，J＝9Hz，J＝8.7Hz)；4.61-4.54(d，2H，J＝2.1Hz)；4.31(m，2H)；3.21(s，1H)；3.04(s，1H)；2.41(m，1H)；2.19(m，1H)；1.97(m，1H)；1.70(m，1H)；1.30(m，3H).
MASS：188.1
Embodiment 10
(1R, 3S, 4S)-5, the preparation of 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl esters
Operation steps: with compound (1R, 3S, 4S)-5, (0.68g 2mmol) is dissolved in the 20mL dehydrated alcohol 5-two fluoro-2-carbobenzoxy-(Cbz)s-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester, adds 10% palladium/carbon of 0.1g, reaction is spent the night under 40 ℃ in 0.5 atmospheric hydrogen, reacted after-filtration and removed catalyzer, revolve inspissation contract product 0.40g, productive rate is 96.9%.
MASS：206.1(M+1)
Embodiment 11
((1R, 3S, 4S, 5S)-preparation of 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylate methyl ester
Reaction formula:
Specifically with reference to embodiment 10, reaction solvent methyl alcohol, catalyzer is with 10% palladium hydroxide/carbon, 30 ℃ of temperature of reaction, and productive rate is 94.3%.
MASS：174.1(M+1)
Embodiment 12
(1R, 3S, 4S)-5, the preparation of 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester hydrochlorides
Reaction formula:
Operation steps: with compound (1R, 3S, 4S)-5, (0.30g 1mmol) is dissolved in the 20mL salt acid ether 5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester, stirs 2 hours.Reaction solution be spin-dried for product (1R, 3S, 4S)-5,5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester hydrochloride 0.24g, productive rate is 99.6%.
HNMR(CDCl3)δ：11.24(s，1H)；9.38(s，1H)；4.70(s，1H)；4.33(m，2H)；4.19(d，1H，J＝3.9Hz)；2.91(d，1H，J＝10.8Hz)；2.17(m，3H)；2.06(s，2H)；1.33(m，3H).
MASS：206.1(M+1)
Embodiment 13
(1R, 3S, 4S)-5, the preparation of 5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid
Reaction formula:
Operation steps: with compound (1R, 3S, 4S)-5, (0.306g 1mmol) is dissolved in 10mL methyl alcohol and the 2mL water 5-two fluoro-2-tertbutyloxycarbonyls-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, adds sodium hydroxide (0.08g again, 2mmol), reaction solution at room temperature stirs and spends the night.After reaction is finished, revolve to steam and remove methyl alcohol, use extracted with diethyl ether, water is transferred pH to 7 with the hydrochloric acid soln of 1mol/L, and lyophilize gets product 0.248g, and productive rate is 91.0%.
HNMR(CDCl3)δ：4.29(d，1H，J＝13.6Hz)；4.08(d，1H，J＝13.2Hz)；2.94(m，1H)；2.19-2.01(m，3H)；1.78(m，1H)；1.45(m，9H).
MASS：276.1(M-1)
Embodiment 14
(1R, 3S, 4S, 5R)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
The first step reaction: (1R, 3S, 4S, 5S)-preparation of 5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: with compound (1R, 3S, 4S)-2-tertbutyloxycarbonyl-5-carbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (1.41g, 5mmol) be dissolved in the 50mL dehydrated alcohol, be cooled to 0 ℃, again to the sodium borohydride that wherein adds 0.4g, stir half an hour, reaction finishes.Add saturated ammonium chloride solution stopped reaction, add the methylene dichloride of 30mL again, the extraction separatory.The organic phase anhydrous sodium sulfate drying revolves inspissation and contracts, obtain product (1R, 3S, 4S, 5S)-5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 1.2g, productive rate is 83.9%.
The second step reaction: (1R, 3S, 4S, 5R)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Operation steps: at-78 ℃, with (1R, 3S, 4S, 5S)-(1.42g 5mmol) is dissolved in the dichloromethane solution that the 10mL methylene dichloride is added drop-wise to 1mLDAST 5-hydroxyl-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester, stirred 6 hours at-78 ℃, be raised to ambient temperature overnight.After reaction finishes, saturated sodium bicarbonate solution is added in the reaction solution, organic phase is washed with saturated common salt, and anhydrous sodium sulfate drying concentrates, cross post, get product (1R, 3S, 4S, 5R)-and 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester 0.75g, productive rate is 52.0%.
HNMR(CDCl3)δ：4.92-4.71(dd，1H，J＝5.4Hz，J＝5.4Hz)；4.32(s，1H)；4.15(m，2H)；3.58(m，1H)；2.82(s，1H)；2.12-1.80(m，2H)；1.39(m，9H)；1.22(m，3H).
MASS：288.2
Embodiment 15
(1R, 3S, 4S, 5R)-preparation of 5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid
Reaction formula:
Operation steps: with compound (1R, 3S, 4S, 5R)-5-fluoro-2-tertbutyloxycarbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester (0.28,1mmol) be dissolved in 15mL methyl alcohol and the 0.5mL water, add powder salt of wormwood 2 gram again, at room temperature stir and spend the night.After reaction is finished, remove by filter salt of wormwood, revolve to steam and remove methyl alcohol, add 20ml water, transfer pH to 3, use ethyl acetate extraction with the hydrochloric acid soln of 0.5mol/L, the dry product 0.22g that gets of cryoconcentration, productive rate is 85.3%.
HNMR(CDCl3)δ：4.23(d，1H，J＝11.7Hz)；3.50(s，1H)；2.81(m，1H)；2.10-1.90(m，2H)；1.85-1.60(m，3H)；1.45(m，9H).
MASS：258.1(M-1)
Embodiment 16
(1R, 3S, 4S, 5R)-preparation of 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid, ethyl ester
Reaction formula:
Specifically with reference to embodiment 10, reaction solvent ethanol, catalyzer is with 10% palladium hydroxide/carbon, 30 ℃ of temperature of reaction, and productive rate is 89.1%.
HNMR(CDCl3)δ：0.55-9.50(m，1H)；8.5(s，1H)；5.10(m，1H)；4.68-4.21(m，3H)；4.01(m，1H)；3.75(m，3H)；3.15(m，1H)；3.08-2.69(m，1H)；1.77-2.11(m，4H)；1.42(m，3H).
MASS：188.1.
Claims (10)
1, fluoro or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: chemical structural formula is as follows:
R
1For replacing functional group or amino protecting group, be selected from hydrogen, 2, a kind of in 4-dimethoxy-benzyl, benzyl, tertbutyloxycarbonyl or the carbobenzoxy-(Cbz);
R2 is selected from hydrogen, methyl for replacing functional group, ethyl, benzyl or 2, a kind of in the 4-dimethoxy-benzyl;
X is fluorine atom or hydrogen.
2, the preparation method of described fluoro of claim 1 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: reactions steps is as follows:
In above-mentioned technology, 5-hydroxyl-2-azabicyclo [2.2.1] heptane-3-carboxylicesters or 5-carbonyl-2-azabicyclo [2.2.1] heptane-3-carboxylicesters are obtained 5-fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylicesters or 5 through fluoridation, 5-two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylicesterss, obtain carboxylic acid through hydrolysis again, if slough protection, just can obtain the free aminocompound,, obtain target product through changing the conversion of protecting group or ester group;
PG represents protecting group in the formula, is 2, a kind of in 4-dimethoxy-benzyl, benzyl, tertbutyloxycarbonyl or the carbobenzoxy-(Cbz);
Rn is a kind of in methyl, ethyl or the benzyl.
3, the preparation method of fluoro according to claim 2 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: described fluoridation, the solvent of its reaction usefulness is an aprotic solvent, be selected from ether, propyl ether, butyl ether, dioxane, 1, in 2 dimethoxy ether, methylene dichloride, 1,2 ethylene dichloride, chloroform, tetrahydrofuran (THF), benzene and the toluene one or more; Temperature of reaction is from-78 ℃ to 120 ℃; Reaction reagent is one or both in diethylin sulfur trifluoride, two (methoxy ethyl) amido sulfur trifluoride, 4-morpholine sulfur trifluoride, two (4-morpholinyl) bifluoride sulphur and the triphenyl phosphorus/Potassium monofluoride.
4, the preparation method of fluoro according to claim 3 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: the reaction solvent of fluoridation is methylene dichloride or ether.
5, the preparation method of fluoro according to claim 3 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: the reagent of fluoridation is the diethylin sulfur trifluoride.
6, the preparation method of fluoro according to claim 2 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative; it is characterized in that: wherein the protecting group of indication is 2, a kind of in 4-dimethoxy-benzyl, benzyl, tertbutyloxycarbonyl or the carbobenzoxy-(Cbz).
7, the preparation method of fluoro according to claim 2 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative; it is characterized in that: the deprotection base of indication wherein; method with catalytic hydrogenation removes 2; a kind of protecting group in 4-dimethoxy-benzyl, benzyl or the uncle's carbobenzoxy-(Cbz); remove 2 with hydrochloric acid or trifluoracetic acid, two kinds of protecting groups of 4-dimethoxy-benzyl and tertbutyloxycarbonyl.
8, the preparation method of fluoro according to claim 2 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative, it is characterized in that: described hydrolysis reaction, its solvent is methyl alcohol, ethanol, propyl alcohol, Virahol, butanols, isopropylcarbinol, the trimethyl carbinol, methyl cellosolve, acetone, butanone, ether, dioxane, tetrahydrofuran (THF), N, one or both mixtures in dinethylformamide, methyl-sulphoxide and the water, the used alkali of hydrolysis is NaOH, KOH, LiOH, Na
2CO
3, K
2CO
3Or Li
2CO
3In a kind of, the temperature of hydrolysis reaction is from room temperature to 100 ℃.
9, the preparation method of fluoro according to claim 8 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative is characterized in that: the temperature of hydrolysis reaction is a room temperature to 60 ℃.
10, the intermediate during described fluoro of claim 1 or two fluoro-2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative synthesizes as medicine or the application of structure fragment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100946047A CN101462999A (en) | 2007-12-21 | 2007-12-21 | Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100946047A CN101462999A (en) | 2007-12-21 | 2007-12-21 | Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101462999A true CN101462999A (en) | 2009-06-24 |
Family
ID=40803819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100946047A Pending CN101462999A (en) | 2007-12-21 | 2007-12-21 | Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101462999A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| WO2011112429A1 (en) | 2010-03-09 | 2011-09-15 | Schering Corporation | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| CN104098504A (en) * | 2013-04-02 | 2014-10-15 | 上海药明康德新药开发有限公司 | 5, 6-difluoro-2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative and preparation method |
-
2007
- 2007-12-21 CN CNA2007100946047A patent/CN101462999A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| WO2011112429A1 (en) | 2010-03-09 | 2011-09-15 | Schering Corporation | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| CN104098504A (en) * | 2013-04-02 | 2014-10-15 | 上海药明康德新药开发有限公司 | 5, 6-difluoro-2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU660930B2 (en) | (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid | |
| RU2351596C2 (en) | N-[heteroaryl(piperidine-2-yl)methyl]benzamide derivatives and application in therapy | |
| EP1680421B1 (en) | Use of tricyclic compounds as glycine transport inhibitors | |
| CN108395443B (en) | Cyclic compounds inhibiting programmed death receptor ligand 1 and uses thereof | |
| EP1551803B1 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
| EP1682503A2 (en) | Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| EP1680400A2 (en) | Derivatives of n-[ phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[ (azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
| CN108517001A (en) | Water-soluble allopregnenolone derivative and application thereof | |
| WO2017133620A1 (en) | Suvorexant intermediate and preparation method thereof | |
| JP2017043636A (en) | Method for producing thietane amine | |
| CN101462999A (en) | Fluoro or difluoro-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof | |
| CN101463007A (en) | Fluoro or difluoro-2-azabicyclo [2.2.2] octane-3-carboxyl acid derivative and preparation | |
| Scapecchi et al. | Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs | |
| Artale et al. | Synthesis of substituted conformationally constrained 6, 5-and 7, 5-fused bicyclic lactams as dipeptide mimics | |
| CN101463000A (en) | 5-amino-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivatives, and preparation thereof | |
| EP2672821B9 (en) | Cathepsin c inhibitors | |
| CN101463001A (en) | Octahydro cyclopenteno [c] pyrroletetrazole derivative and preparation thereof | |
| CN102971286B (en) | Be used for the treatment of the new organization proteolytic enzyme S protein enzyme inhibitors of such as autoimmune disorder, allergy and chronic pain symptom | |
| CN101463002A (en) | Dihydroxy-2-azabicyclo [2.2.1] heptane-3-carboxyl acid derivative and preparation | |
| CN101463006A (en) | 2-azabicyclo [2.2.2] octane-3-carboxyl acid derivative and preparation | |
| CN110698420B (en) | Preparation method of 2-oxazole methylamine heterocyclic compound | |
| CN108395396A (en) | A kind of preparation method of chirality vicinal amino alcohols intermediate and antagonist and the like | |
| US20070037845A1 (en) | Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof | |
| CN104098504A (en) | 5, 6-difluoro-2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative and preparation method | |
| CN102875535B (en) | 1,5-[(replacement)-methano]-tetrahydro-1 H-pyrrolo [1,2-c]-imidazoles-3 (2H)-one derivant and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090624 |